Phase 3 study of IBI 128
Latest Information Update: 11 Jan 2024
At a glance
- Drugs IBI 128 (Primary)
- Indications Hyperuricaemia
- Focus Therapeutic Use
Most Recent Events
- 27 Dec 2023 According to an Innovent Biologics media release, IBI128 (XOI inhibitor) for the treatment of hyperuricemia is also in global Phase 3 clinical trials.
- 04 Apr 2023 New trial record
- 29 Mar 2023 According to an Innovent Biologics media release, the company expect to initiate this trial in 2023.